Biotechnology 14 May 2026 - 24 May 2026

Crinetics Stock Trades Flat Ahead of June Investor Event
···

Crinetics Stock Trades Flat Ahead of June Investor Event

CRNX closed Friday at $36.80, nearly flat for the week, with a market cap near $3.83 billion. Crinetics will attend the Jefferies Global Healthcare Conference in New York on June 2-4. U.S. stock markets are closed Monday for Memorial Day. The company reported first-quarter revenue of $10.7 million, driven by its Palsonify launch, but posted a net loss of $127.8 million.
May 25, 2026
GeneDx Shares Watch After Holder Filings in Holiday Week
···

GeneDx Shares Watch After Holder Filings in Holiday Week

GeneDx shares closed at $47.31 Friday, up 16% from last week but still 30% below early May levels after a post-earnings drop. SEC filings show Eli Casdin and Keith Meister now hold 13.7% and 17.9% stakes, respectively, after recent open-market purchases. The company cut 2026 revenue guidance and reported Q1 revenue of $102.3 million, missing expectations by $12 million. U.S. markets reopen Tuesday after Memorial Day.
May 24, 2026
Lunai Bioworks Heads Into Key Week After Reverse Split, Ongoing Court Battle
···

Lunai Bioworks Heads Into Key Week After Reverse Split, Ongoing Court Battle

Lunai Bioworks closed at $2.26 Friday, down 2.62%, after a 1-for-8 reverse split aimed at regaining Nasdaq compliance. A Delaware magistrate judge granted Lunai expedited discovery over alleged naked short selling. Nasdaq will remain closed Monday for Memorial Day. Lunai continues to face listing deadlines and reported a $2.57 million net loss for the March quarter.
May 24, 2026
Ocugen Shares Flat Ahead of Holiday-Shortened Week for Eye-Therapy Bid
····

Ocugen Shares Flat Ahead of Holiday-Shortened Week for Eye-Therapy Bid

Ocugen shares closed Friday at $1.34 with 3.9 million shares traded, little changed ahead of the Memorial Day break. The company recently closed a $130 million convertible note sale, using $32.7 million to repay debt and reserving the rest for general purposes. Ocugen will present at the Stifel 2026 Virtual Ophthalmology Forum on Tuesday. The company has completed enrollment in two late-stage eye-disease programs.
May 24, 2026
NovoCure Stock Still Up Ahead of Cancer Trial Data
····

NovoCure Stock Still Up Ahead of Cancer Trial Data

NovoCure shares closed at $17.96 Friday, up 0.3%, and slipped to $17.71 after hours ahead of the Memorial Day market closure. The stock remains about 50% above its April 29 close, after the company raised its 2026 revenue forecast and reported Q1 revenue of $174.1 million. NovoCure had 4,791 active patients at March’s end, including 83 on its new pancreatic cancer device.
May 24, 2026
Kodiak Sciences Falls Before Holiday Pause With Eyes on Drug Update
···

Kodiak Sciences Falls Before Holiday Pause With Eyes on Drug Update

Kodiak Sciences shares fell 3.2% to $36.23 Friday, ending a volatile week ahead of a three-day U.S. market closure. No new company updates were posted; investors await late-stage trial results for Zenkuda, Kodiak’s experimental retina drug. The stock remains above pre-March levels, after Zenkuda met a key Phase 3 goal for diabetic retinopathy. One-year data from a wet AMD trial is expected in September.
May 22, 2026
BioAge Stock Dropped Before June Investor Call on Key Drug
···

BioAge Stock Dropped Before June Investor Call on Key Drug

BioAge Labs shares fell 0.8% to $16.61 Friday, trailing a stronger Nasdaq. The company set June 4 investor meetings but released no new clinical data. Investors are watching for two mid-2026 proof-of-concept trials of BGE-102, its oral NLRP3 inhibitor for cardiovascular and retinal diseases. April Phase 1 data showed at least 85% median reductions in hsCRP, with no serious adverse events.
May 22, 2026
Caribou Biosciences Holds Near $2 With June Cancer Drug Updates Ahead
···

Caribou Biosciences Holds Near $2 With June Cancer Drug Updates Ahead

Caribou Biosciences shares rose about 1% to $2.01 on Friday ahead of cancer drug data updates expected in June. The company plans to present new results on vispa-cel and CB-011 at the European Hematology Association meeting. Caribou had $118.6 million in cash at March 31 and raised $2.3 million by selling 1.08 million shares in the first quarter. The stock traded before a three-day U.S. market holiday.
May 22, 2026
Xenetic Biosciences Shares Edge Down Ahead of ASCO Update
···

Xenetic Biosciences Shares Edge Down Ahead of ASCO Update

Xenetic Biosciences shares slipped 4 cents to $2.90 in thin early Nasdaq trading Friday, with only 144 shares changing hands. The company holds $7.3 million in cash and is set to present cancer drug research at an ASCO poster session on June 1. Xenetic is still considering strategic alternatives. First-quarter royalty revenue rose 36% to $807,000, while net loss narrowed to $456,000.
May 22, 2026
Ultragenyx (RARE) Moves Before Friday’s Bell
···

Ultragenyx (RARE) Moves Before Friday’s Bell

Ultragenyx shares rose to $24.06 in premarket trading after Cantor Fitzgerald raised its price target to $96 and increased the probability of success for GTX-102, its Angelman syndrome drug, to 60%. The company expects Phase 3 data for GTX-102 in the second half of 2026 and has two biologics license applications under FDA review.
May 22, 2026
Tyra Biosciences Stock Has a Data Question Investors Can’t Ignore
···

Tyra Biosciences Stock Has a Data Question Investors Can’t Ignore

Tyra Biosciences shares traded at $33.02 ahead of Friday’s Nasdaq session, below their 52-week high of $40.65. The company reported $383.5 million in cash at March 31 and a first-quarter net loss of $39.3 million. Three Phase 2 trials of dabogratinib are underway or planned, with initial bladder-cancer data expected in August. Wolfe Research initiated coverage this week, citing potential peak sales of $300–400 million.
May 22, 2026
Bio-Techne Shares Bounce, Investors Eye a Key Risk
···

Bio-Techne Shares Bounce, Investors Eye a Key Risk

Bio-Techne closed Wednesday at $46.70, up 2.7%, marking a three-day rebound but still 35% below its January high. Fiscal third-quarter revenue fell 2% to $311.4 million, missing Wall Street estimates as weak biotech demand and U.S. academic funding cuts weighed on sales. CEO Kim Kelderman described the academic market as “frail” and not on a clear recovery path. Bio-Techne owns 20% of Wilson Wolf and may acquire the rest.
May 21, 2026
Vanda Shares Move in Pre-Market Ahead of Nereus and Bysanti Data
···

Vanda Shares Move in Pre-Market Ahead of Nereus and Bysanti Data

Vanda Pharmaceuticals shares fell 0.5% to $6.15 in premarket trading Thursday, trimming part of Wednesday’s 3.2% gain. First-quarter net product sales rose 3% to $51.7 million, but the company posted a $48.6 million net loss and used $50.2 million in operating cash. Vanda raised 2026 revenue guidance to $240–$290 million, expecting Nereus to contribute up to $30 million this year.
May 21, 2026
Neurogene Trades Around $27 With Street Watching Rett Data Test Midyear
···

Neurogene Trades Around $27 With Street Watching Rett Data Test Midyear

Neurogene Inc. shares closed at $26.95 Wednesday, up 0.3%, with little movement before Thursday’s Nasdaq open. About 90% of participants have been dosed in the registrational Embolden trial for NGN-401, with completion expected in Q2. Neurogene reported $243.2 million in cash as of March 31, enough to fund operations into early 2028. The company’s latest filings were posted May 12, with no new updates since.
May 21, 2026
ARGX Stock Watch: Argenx Up Ahead of Immunovant Trial Data
···

ARGX Stock Watch: Argenx Up Ahead of Immunovant Trial Data

argenx SE shares rose 0.7% to $803.67 Wednesday, trailing biotech peers after Immunovant reported positive rheumatoid arthritis trial data for IMVT-1402, sending its stock up 35.1%. VYVGART sales reached $1.3 billion last quarter. The FDA recently expanded VYVGART’s approval for generalized myasthenia gravis. argenx’s next key data releases are expected later this year.
May 20, 2026
CSL Limited Share Price Slides Again as $5 Billion Writedown Puts Biotech Turnaround on the Clock
···

CSL Limited Share Price Slides Again as $5 Billion Writedown Puts Biotech Turnaround on the Clock

CSL Limited shares closed at A$97.26 on Thursday, down 1.55%, extending losses after a profit downgrade and plans for US$5 billion in writedowns. The stock hit its lowest level since January 2017 earlier in the week. CSL cut its FY26 revenue outlook to US$15.2 billion and expects further pressure from U.S. immunoglobulin inventory and lower albumin prices in China.
May 14, 2026
1 2 3

Stock Market Today

  • Farmers Oppose Battery Storage Projects on Agricultural Land in Victoria
    May 24, 2026, 6:27 PM EDT. Farmers in Victoria's west Gippsland region are opposing plans to build large battery energy storage systems (BESS) on prime agricultural land. Samsung C&T Renewable Energy Australia, Taiwan-based ZEBRE, and German company ib vogt have applied to develop projects ranging from 200 to 360 megawatts. These batteries store electricity and release it during peak demand but do not generate power. Local farmers like James Faithful cite concerns over loss of productive land, environmental impacts, noise, and visual disruption. Baw Baw Shire Council supports renewable energy but urges the government to avoid siting battery systems on farmland, seeking better policies that balance clean energy with agriculture and community interests.